Since oral drug delivery is convenient, affordable, and patient-compliant, it continues to be the most used method. However, taking medications can be difficult for both young and old, increasing the danger of choking. Since its introduction in the 1970s, buccal mucosal dosage forms and fast-dissolving drug delivery systems (FDDS) have improved in terms of usability and safety. Fast-dissolving oral films (OFDFs) are one of them that have become more well-liked due to their capacity to dissolve on the tongue rapidly without the need for water or chewing, enhancing self-administration. Improved bioavailability, decreased first-pass metabolism, quick onset of action, and compatibility with water-insoluble medications are just a few of the many benefits that OFDFs provide. They can be made using solvent casting, hot-melt extrusion, rolling, or solid dispersion extrusion procedures, and they can be prepared with polymers, plasticisers, surfactants, sweeteners, and flavor/color agents. Controlled or targeted release is provided by innovations such multilayered, mucoadhesive, and nanotechnological films (e.g., containing nanoparticles or cyclodextrin complexes). OFDFs appeal to a wide range of patients, including youngsters, migraineurs, and those with Parkinson's and Alzheimer's diseases. Strict quality, packaging, and labelling standards are guaranteed by regulatory guidelines issued by organisations like the FDA, CDSCO, and EMA. Film performance is assessed using characterisation techniques such as morphology, thickness, tensile strength, disintegration, moisture uptake, in vitro dissolution, and palatability. New technologies like as WafertabTM, SoluleavesTM, and FoamburstTM, customised and stimulus-responsive films, and environmentally friendly production techniques show great promise as the area develops. This review highlights OFDFs' expanding importance in patient-centric treatments by synthesising recent advancements and potential future approaches. Keywords: Fast dissolving, Oral film, Drug delivery, regulatory agencies.
Sharma et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: